Media365
China’s healthcare sector has been drawing offshore capital to Hong Kong-listed stocks as investors look for safe havens amid global volatility in commodities.
“Although the Middle East conflict has created a lot of uncertainty and volatility in the overall market, we have seen investor interest in China healthcare start to improve in the past two weeks, given that healthcare is generally more insulated from commodity prices than many other industries,” said Yang Huang, head of China healthcare research at JPMorgan Chase.
Brent crude jumped to a peak of US$121.88 per barrel in March before retreating to US$98.66 on Thursday, while West Texas Intermediate traded at US$97.40 a barrel.
The healthcare sector’s improving fundamentals were also providing a tailwind, according to analysts.
China’s biotech subsector posted revenue and net profit growth of 36 per cent and 103 per cent, respectively, in 2025, driven by commercialisation and licensing deals, Huang said.
